CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Incyte Corporation
Dren Bio
AVM Biotechnology Inc
Lyell Immunopharma, Inc.
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Hackensack Meridian Health
Artiva Biotherapeutics, Inc.
AvenCell Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
University of Iowa
Vironexis Biotherapeutics Inc.
Pfizer
Taiho Oncology, Inc.